20xx年醫(yī)學(xué)專題—乳腺癌解救化療(編輯修改稿)
2024-11-04 17:27 本頁面
【文章內(nèi)容簡介】 ，共六十四頁。,治療(zh236。li225。o)方案,GP1 GEM 1250 mg/m2 D1+8 P 175 mg/m2 as 3h inf D1 GP2 GEM 1000 mg/m2 D1+8 P 100 mg/m2 as 1h inf D1+8 GD GEM 1000 mg/m2 D1+8 D 40 mg/m2 as 1h inf D1+8 Repeated every three weeks Maximum number of cycles allowed by protocol, 8,分組,,第三十頁，共六十四頁。,基線(jīxi224。n)情況,GP1 GP2 GD Total (N=72) (N=67) (N=65) (N=204) Age (years) Median 48 47 48 48 Range 2972 2371 2077 2077 KPS Mean 88 88 89 88 Range 70100 70100 70100 70100,第三十一頁，共六十四頁。,基線(jīxi224。n)情況 (%),GP1 GP2 GD Total (N=72) (N=67) (N=65) (N=204) Dominant site of disease Visceral 71 72 68 70 Liver 32 42 32 35 Bone 8 9 8 8 Soft tissue 21 19 25 22 Number of disease sites 1 24 19 14 19 2 28 27 34 29 ?3 49 54 52 52,第三十二頁，共六十四頁。,初期(chūqī)治療 (%),GP1 GP2 GD Total (N=72) (N=67) (N=65) (N=204) Anthracyclines 100 99 100 99 For MBC (+/adj a) 39 56 45 47 Taxanes (adj) 0 0 1.5 0.5 Other regimens 32 37 25 31 Endocrine therapy 35 45 43 41 For MBC (+/adj) 24 31 35 30 a Includes neoadjuvant,第三十三頁，共六十四頁。,有效率 (%),GP1 GP2 GD Total (N=72) (N=67) (N=65) (N=204) CR 4.2 6.0 4.6 4.9 PR 44.4 46.3 47.7 46.1 RR (%) 48.6 52.2 52.3 51.0 SD 18.1 19.4 10.8 17.2 PD 20.8 19.4 10.8 17.2 Not donea 9.7 4.5 7.7 7.4 Unknown 2.8 4.5 6.2 4.4 a Study therapy discontinued before first response assessment,第三十四頁，共六十四頁。,腫瘤(zhǒngli)進(jìn)展時間,GP1 GP2 GD Total TTP (ms) 7.5 7.0 7.4 7.1,第三十五頁，共六十四頁。,3/4級血液毒性(d x236。nɡ)反應(yīng) (%),GP1 GP2 GD Total N=72 N=68 N=68 N=208 Grade 3 4 3 4 3 4 3 4 Neutrophils 46 18 40 18 37 31 41 22 G 3+4 64 58 68 63 Platelets 17 1 15 0 22 0 18 1 Hb 8 0 9 1 19a 4a 12 2 a P = 0.0261,,第三十六頁，共六十四頁。,3/4級非血液毒性(d x236。nɡ)反應(yīng) (%),GP1 GP2 GD Total N=72 N=68 N=68 N=208 Grade 3 4 3 4 3 4 3 4 Febrile 0 0 3 1 7a 4a 3 2 Infection 1 5 4 1 13a 7a 6 5 Bleeding 0 1 0 1 1 1 1 1 a P = 0.0037,,第三十七頁，共六十四頁。,總的3/4級毒性(d x236。nɡ)反應(yīng) (%),GP1 GP2 GD Total N=72 N=68 N=68 N=208 Grade 3
范文總結(jié)相關(guān)推薦
鄂ICP備17016276號-1